---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-046889"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:52:27.579714+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics President & Chairman Novak to resign Sept 15; CEO Kulkarni to become Chairman

## Summary
- Rodger Novak resigns as President and Chairman, effective September 15, 2023; no dispute or disagreement cited.
- Samarth Kulkarni, Ph.D., CEO, appointed Chairman of the Board effective same date; will continue as CEO.
- Novak co-founded CRISPR nearly 10 years ago, was instrumental in key collaborations and exa-cel development.
- Kulkarni's compensation arrangement remains unchanged; Board thanks Novak for his leadership.
- CRISPR's exa-cel for sickle cell disease and beta thalassemia is under regulatory review for potential first CRISPR-based medicine approval.

## SEC filing metadata
- accession: 0000950170-23-046889
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/0000950170-23-046889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/crsp-20230904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-046889
- JSON: https://secwatch.observer/filing/0000950170-23-046889.json
- Plain text: https://secwatch.observer/filing/0000950170-23-046889.txt

## Key facts
- Executive change
  Rodger Novak resigned as President and Chairman at CRISPR Therapeutics AG.
  - Action: resigned
  - Role: President and Chairman
  source text: On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/0000950170-23-046889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.